Clinical trials
Unresectable Breast Cancer clinical trials
Below are recruiting unresectable breast cancer clinical trials, each written for real people, not researchers. We’re tracking 263 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Scottsdale, ArizonaAges 18 years+ - NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT03872661RecruitingPhase 2
New lung cancer medicines before surgery for unresectable stage III
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Guangzhou, GuangdongAges 18–75 - NCT06792162RecruitingPhase 2
Immunotherapy and targeted therapy trial for advanced gastric cancer
This trial tests a combination of two drugs: carilizumab (an immunotherapy) and apatinib (a targeted therapy) for patients with unresectable stage III or IV gastric cancer that has a specific DNA repair problem (dMMR). The goal is to see if this treatment can help shrink tumors and improve outcomes.
BeijingAges 18 years+ - NCT06843967RecruitingPhase 1/Phase 2
Mirdametinib and palbociclib for liposarcoma
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Basking Ridge, New JerseyAges 18 years+ - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75 - NCT06749730RecruitingPhase 2
Study of four drugs for advanced bile duct cancer
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
ZhengzhouAges 18–80 - NCT07609121RecruitingPhase 2
Radiation, Chemotherapy, and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT07221942RecruitingPhase 2
Pembrolizumab and Enfortumab Vedotin for Advanced Bladder Cancer
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06676527Recruiting
Vorolanib for advanced kidney cancer after first treatment
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Nanjing, JiangsuAges 18–80 - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+
Hear when a new Unresectable Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable breast cancer?
- Yes. Clin2 currently lists 263 recruiting unresectable breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.